Equities research analysts forecast that Neon Therapeutics Inc (NASDAQ:NTGN) will post ($0.76) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Neon Therapeutics’ earnings. The highest EPS estimate is ($0.66) and the lowest is ($0.84). Neon Therapeutics reported earnings of ($7.84) per share in the same quarter last year, which would indicate a positive year over year growth rate of 90.3%. The business is expected to report its next quarterly earnings results on Monday, August 5th.

According to Zacks, analysts expect that Neon Therapeutics will report full-year earnings of ($2.70) per share for the current year, with EPS estimates ranging from ($3.33) to ($1.83). For the next year, analysts expect that the company will post earnings of ($2.80) per share, with EPS estimates ranging from ($4.26) to ($1.96). Zacks’ EPS averages are an average based on a survey of research firms that cover Neon Therapeutics.

Neon Therapeutics (NASDAQ:NTGN) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.76) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.73) by ($0.03).

Several research analysts recently commented on the company. Berenberg Bank assumed coverage on Neon Therapeutics in a research report on Wednesday, March 27th. They issued a “buy” rating and a $15.00 price target for the company. Zacks Investment Research lowered Neon Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 16th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $17.43.

NTGN opened at $5.60 on Monday. The stock has a market capitalization of $153.27 million and a P/E ratio of -1.01. Neon Therapeutics has a 12 month low of $4.20 and a 12 month high of $16.23.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NTGN. Hillhouse Capital Advisors Ltd. bought a new stake in Neon Therapeutics in the fourth quarter worth about $1,572,000. FMR LLC lifted its stake in Neon Therapeutics by 1.1% in the fourth quarter. FMR LLC now owns 2,079,669 shares of the company’s stock worth $10,461,000 after purchasing an additional 23,075 shares during the last quarter. BlackRock Inc. lifted its stake in Neon Therapeutics by 12.0% in the fourth quarter. BlackRock Inc. now owns 307,782 shares of the company’s stock worth $1,548,000 after purchasing an additional 32,943 shares during the last quarter. Vanguard Group Inc. lifted its stake in Neon Therapeutics by 215.9% in the third quarter. Vanguard Group Inc. now owns 197,414 shares of the company’s stock worth $1,686,000 after purchasing an additional 134,914 shares during the last quarter. Finally, Vanguard Group Inc lifted its stake in Neon Therapeutics by 215.9% in the third quarter. Vanguard Group Inc now owns 197,414 shares of the company’s stock worth $1,686,000 after purchasing an additional 134,914 shares during the last quarter. Institutional investors own 70.50% of the company’s stock.

About Neon Therapeutics

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

Read More: What are earnings reports?

Get a free copy of the Zacks research report on Neon Therapeutics (NTGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neon Therapeutics (NASDAQ:NTGN)

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.